Rodman & Renshaw Fireside Chat | November 2026 - AGENUS INC

Explicit Guidance:

• Financial Milestones & Warrants: Series A warrants (expiring 30 days after 60 patients enrolled in Robin trial) expected to expire in Q2 2027, triggering $85 million gross proceeds if exercised at $4.02/share; proceeds extend cash runway through Q1 2029. Series B warrants (triggered by Q4 2028 interim readout) offer potential for $170 million proceeds at $5.03/share; exercisability contingent on Series A exercise.
• Valuation Framework: Management projects a total U.S. addressable market exceeding $7 billion for the neoadjuvant MSS colon cancer setting, assuming a therapy cost of approximately $200,000 per course (comparable to perioperative Keytruda).
• Clinical Endpoints (Financial Proxy): Target hazard ratio of 0.65 for Event-Free Survival (EFS) in the Robin Phase 3 trial; projected pathologic complete response (pCR) rate of ~17% to achieve this HR, based on correlation with prior neoadjuvant studies.

Business-Segment Outlook:

• Pipeline Progression: Primary focus is the Robin Phase 3 trial (850 patients, randomizing MSS high-risk stage 2/3 colon cancer to Bot-Bel vs. standard care) with the following timeline: First patient enrollment anticipated Q1 2026 (note: transcript says "Q1 of this year" in context of a 2026 call, likely referring to current year, but timeline logic suggests 2026/2027 sequence based on Q2 2027 enrollment milestone); 60-patient enrollment milestone (warrant trigger) in Q2 2027; Interim pCR analysis of first 100 patients in Q4 2028; Primary EFS interim readout (75% events) in H2 2029; Full EFS readout in H2 2030.
• Therapeutic Expansion: Potential to expand into MSI-High colon cancer and other cold tumors (sarcoma, ovarian, triple-negative breast cancer) if Robin data validates the mechanism; ongoing Investigator-Initiated Studies (IIS) in neoadjuvant MSS rectal cancer (e.g., Memorial Sloan Kettering) and NeoASIS (pan-tumor, MSS cohort) are expected to yield data in 2027.
• Treatment De-escalation: Anticipation of reduced chemotherapy usage (specifically oxaliplatin de-escalation) in patients achieving pCR or lymph-node negativity post-Bot-Bel, potentially eliminating the need for adjuvant chemo in a subset of patients compared to standard of care.

Market and Competitive Outlook:

• Competitive Landscape: Anticipates a "renaissance" in CTLA-4 assets with competitors introducing activated FC or masked CTLA-4 antibodies; GenS asserts a substantial clinical lead and scientific validation advantage.
• Demand Trends: Significant unmet need in MSS colon cancer, a population representing ~85% of metastatic cases with no therapeutic advancements in 20 years. Management expects robust site interest and enrollment due to the "cold tumor" targeting capability which differentiates the product from existing PD-1/VEGF therapies.
• Regulatory Strategy: Trial design aligns with FDA expectations (modeled on Foxtrot study) using standard of care (surgery + chemo) as control; FDA agreed to tumor-stage guided adjuvant chemo in control arm, ensuring patient safety and standardizing comparator.

Macro / Industry Outlook:

• Immuno-oncology Shift: Management views the industry as shifting toward "igniting" the immune system in cold tumors, validating the CTLA-4 + PD-1 combination strategy.
• Safety Profile: Anticipated superior tolerability in the neoadjuvant setting (early-stage disease) compared to metastatic setting (C800 study) due to patients having healthier immune systems and lower cumulative prior treatments (single dose vs. 2-4 doses).

Strategic Initiatives:

• Capital Raise (PIPE): Closed $340 million private placement in July (oversubscribed); $85 million upfront, $255 million potential via warrant tranches (Series A/B). All tranches priced at premiums to $3.35/share.
• Site Selection Strategy: Unconventional approach of direct engagement with every prospective site to validate enrollment capability, targeting high-volume centers in U.S., South America, Australia, and Europe; assessing China for potential inclusion but prioritizing "first-world" regulatory markets for initial rollout.
• Global Expansion: Awaiting clinical trial applications for Europe (expected ~1 quarter behind U.S. start) and potential for China enrollment pending regulatory decisions.

Risks and Headwinds to Outlook:

• Trial Execution Risk: Enrollment ramp and site activation timelines are critical for warrant triggers; delay in achieving 60-patient enrollment could defer Series A warrant exercise and subsequent cash infusion.
• Competitive Encroachment: Rapid development of next-generation CTLA-4 assets by other biopharmaceutical companies could erode first-mover advantage.
• Safety/Toxicity: While early data suggests low toxicity in neoadjuvant setting, any safety signal regarding neurotoxicity (oxaliplatin vs. Bot-Bel) or immune-related adverse events (irAEs) in the Robin trial could impact regulatory approval or market adoption.
• Market Access/Reimbursement: Dependence on $200k pricing benchmark; potential pushback on cost-effectiveness if recurrence benefits do not strictly correlate with improved overall survival in long-term follow-up.

Management Tone on the Future:

• High Confidence: Management expresses strong conviction in the "crystallized" value proposition and clear path to first approval, describing the asset as "de-risked" with a validated mechanism of action.
• Strategic Clarity: Tone is focused on fundamental value creation, emphasizing the specific milestones (warrants, data readouts) that will unlock capital and validate the investment thesis.
• Optimism on Efficacy: Belief that Bot-Bel will outperform standard chemotherapy in recurrence rates while reducing toxicity, framed as a significant quality-of-life benefit for patients.

Miscellaneous:

• Translational Data: Current neoadjuvant studies (NEST, UNICORN) show 30% pCR rates in MSS colon cancer and 100% recurrence-free survival in combined cohorts (MSS and MSI-H) with median follow-up of 19-32 months.
• Real-World Access: Bot-Bel is currently available under an access program in France for metastatic colorectal cancer, ovarian cancer, and sarcoma, approved by the ANSM.
• Stock Price Expectation: Management states the stock is currently undervalued relative to the potential market cap driven by the $7B TAM and clinical success.